Biblioteca Hospital 12 de Octubre
Vista normal Vista MARC Vista ISBD

Tumor recurrence and tumor-related mortality in endometrial cancer: Analysis in 276 patients. [artículo]

Por: Tejerizo García, Álvaro [Obstetricia y Ginecología] | Álvarez Conejo, Carmen [Obstetricia y Ginecología] | Muñoz Hernando, Leticia [Obstetricia y ginecología] | Guillén Gámez, Carmen [Obstetricia y Ginecología] | Seoane Ruiz, José Miguel [Obstetricia y Ginecología] | Pérez Sagaseta, Concepción [Obstetricia y Ginecología] | Jiménez López, Jesús Salvador [Obstetricia y Ginecología].
Colaborador(es): Servicio de Obstetricia y Ginecología.
Tipo de material: materialTypeLabelArtículoEditor: Indian journal of cancer, 2015Descripción: 52(4):682-4.Recursos en línea: Solicitar documento Resumen: Background: In this manuscript, we assessed tumor recurrence and tumor-related mortality in a clinical series of endometrial cancer patients. Materials and methods: A retrospective evaluation of 276 patients (mean age 64 years) with histologically confirmed endometrial cancer treated at a single hospital in Madrid (Spain) was conducted. The median follow-up was estimated using the inverse Kaplan-Meier method. Results: Salient findings were endometrioid carcinoma (84.8% of cases), grade G1 (48.9%) and stages IB (35.1%) and IC (23.2%). Myometrial infiltration >50% was documented in 31.2% of cases and lymphovascular space invasion in 11.9%. After surgery, 52.5% of patients were classified into the low risk group, 21.4% into the intermediate risk group and 26.1% into the high risk group. Tumor recurrence occurred in 14.5% of patients, with an estimated median follow-up of 45 months (95% confidence interval (CI): 41.2-48.8), locoregional recurrence in 42.5% and distant recurrences in 57.5%. Furthermore, 40% of tumor recurrences developed during the first year after primary treatment and 90% over the first 3 years of follow-up. The tumor-related mortality rate was 15.9%. The estimated median follow-up was 46 months (95% CI: 43.0-49.0). Furthermore, 5.07% of death because of tumor developed during the first year after primary treatment and 13.77% over the first 3 years of follow-up. Conclusion: The rates of tumor-related death and tumor recurrence in endometrial cancer patients are low, with the highest percentages occurring within 3 years of primary treatment. Most of the recurrences occur outside the pelvis.
Etiquetas de esta biblioteca: No hay etiquetas de esta biblioteca para este título. Ingresar para agregar etiquetas.
    valoración media: 0.0 (0 votos)
Tipo de ítem Ubicación actual Signatura Estado Fecha de vencimiento
Artículo Artículo PC17458 (Navegar estantería) Disponible

Formato Vancouver:
Tejerizo García A, Álvarez Conejo C, Muñoz Hernando L, Guillén Gámez C, Seoane Ruiz JM, Pérez Sagaseta C et al. Tumor recurrence and tumor-related mortality in endometrial cancer: Analysis in 276 patients. Indian J Cancer. 2015 Oct-Dec;52(4):682-4.

PMID: 26960518

Contiene 9 referencias

Background: In this manuscript, we assessed tumor recurrence and tumor-related mortality in a clinical series of endometrial cancer patients.
Materials and methods: A retrospective evaluation of 276 patients (mean age 64 years) with histologically confirmed endometrial cancer treated at a single hospital in Madrid (Spain) was conducted. The median follow-up was estimated using the inverse Kaplan-Meier method.
Results: Salient findings were endometrioid carcinoma (84.8% of cases), grade G1 (48.9%) and stages IB (35.1%) and IC (23.2%). Myometrial infiltration >50% was documented in 31.2% of cases and lymphovascular space invasion in 11.9%. After surgery, 52.5% of patients were classified into the low risk group, 21.4% into the intermediate risk group and 26.1% into the high risk group. Tumor recurrence occurred in 14.5% of patients, with an estimated median follow-up of 45 months (95% confidence interval (CI): 41.2-48.8), locoregional recurrence in 42.5% and distant recurrences in 57.5%. Furthermore, 40% of tumor recurrences developed during the first year after primary treatment and 90% over the first 3 years of follow-up. The tumor-related mortality rate was 15.9%. The estimated median follow-up was 46 months (95% CI: 43.0-49.0). Furthermore, 5.07% of death because of tumor developed during the first year after primary treatment and 13.77% over the first 3 years of follow-up.
Conclusion: The rates of tumor-related death and tumor recurrence in endometrial cancer patients are low, with the highest percentages occurring within 3 years of primary treatment. Most of the recurrences occur outside the pelvis.

No hay comentarios para este ejemplar.

Ingresar a su cuenta para colocar un comentario.

Con tecnología Koha